[

2-[18F]fluoroethylazide Lutathera clinical translation fluorine-18 octreotide positron emission tomography radiopharmaceuticals

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
02 Apr 2020
Historique:
received: 09 03 2020
revised: 26 03 2020
accepted: 31 03 2020
entrez: 8 4 2020
pubmed: 8 4 2020
medline: 8 4 2020
Statut: epublish

Résumé

The success of Lutathera™ ([

Identifiants

pubmed: 32252406
pii: cancers12040865
doi: 10.3390/cancers12040865
pmc: PMC7226534
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Subventions

Organisme : Medical Research Council
ID : MR/J007986/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N020782/1
Pays : United Kingdom

Références

J Nucl Med. 2013 Jun;54(6):855-60
pubmed: 23516312
Onco Targets Ther. 2017 Oct 03;10:4821-4828
pubmed: 29042793
Eur J Nucl Med Mol Imaging. 2003 Jan;30(1):117-22
pubmed: 12483418
Sci Rep. 2019 Dec 17;9(1):19299
pubmed: 31848442
J Nucl Med. 2010 Mar;51(3):454-61
pubmed: 20150268
Bioconjug Chem. 2015 Dec 16;26(12):2350-9
pubmed: 26420336
J Nucl Med. 2018 Jan;59(1):66-74
pubmed: 29025982
EJNMMI Radiopharm Chem. 2020 Jan 29;5(1):4
pubmed: 31997090
Nucl Med Biol. 2012 Oct;39(7):1000-5
pubmed: 22575271
Bioconjug Chem. 2005 Nov-Dec;16(6):1572-9
pubmed: 16287257
J Nucl Med. 2015 Jul;56(7):1100-5
pubmed: 25977461
Bioconjug Chem. 2002 Jul-Aug;13(4):721-8
pubmed: 12121126
Theranostics. 2019 Feb 14;9(5):1336-1347
pubmed: 30867834
Clin Cancer Res. 2004 Jun 1;10(11):3593-606
pubmed: 15173065
J Nucl Med. 2016 Aug;57(8):1207-13
pubmed: 27173162
J Nucl Med. 2006 Apr;47(4):566-73
pubmed: 16595488
Molecules. 2015 Jul 16;20(7):12913-43
pubmed: 26193247
Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):870-880
pubmed: 31492994
Pharmaceuticals (Basel). 2019 Jul 29;12(3):
pubmed: 31362406
Bioconjug Chem. 2007 May-Jun;18(3):989-93
pubmed: 17429938
Drug Discov Today. 2017 Oct;22(10):1572-1581
pubmed: 28676407
Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):72-9
pubmed: 17874094
Appl Radiat Isot. 2013 Jun;76:2-13
pubmed: 23522791
Br J Radiol. 2018 Nov;91(1091):20180440
pubmed: 30179054
Cancer Biother Radiopharm. 2009 Aug;24(4):379-93
pubmed: 19694573
Nat Protoc. 2016 Jun;11(6):1057-66
pubmed: 27172166
J Nucl Med. 2011 Sep;52(9):1441-8
pubmed: 21852355
Bioorg Med Chem Lett. 2011 Dec 1;21(23):6945-9
pubmed: 22030029
Bioorg Med Chem Lett. 2011 May 15;21(10):3122-7
pubmed: 21458258
Semin Nucl Med. 2001 Oct;31(4):296-311
pubmed: 11710772
J Am Chem Soc. 2013 Jan 16;135(2):703-9
pubmed: 23194416
J Nucl Med. 2020 Jan 10;:
pubmed: 31924723
Org Biomol Chem. 2015 Oct 7;13(37):9528-50
pubmed: 26284434
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
Angew Chem Int Ed Engl. 2014 Oct 27;53(44):11876-80
pubmed: 25196467
Eur J Nucl Med Mol Imaging. 2008 Feb;35(2):264-71
pubmed: 17912524
J Nucl Med. 2017 Mar;58(3):451-457
pubmed: 27660147
Bioconjug Chem. 2017 Feb 15;28(2):583-589
pubmed: 28150941
Bioconjug Chem. 2016 Nov 16;27(11):2707-2714
pubmed: 27715017
J Nucl Med. 2014 Sep;55(9):1499-505
pubmed: 24970911
Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2398-2399
pubmed: 31367905
Nuklearmedizin. 2009;48(5):201-7
pubmed: 19639164
J Nucl Med. 2004 May;45(5):892-902
pubmed: 15136641
Appl Radiat Isot. 2018 Mar;133:1-3
pubmed: 29272820
Nucl Med Biol. 2012 Nov;39(8):1175-81
pubmed: 22770647
J Am Chem Soc. 2004 Aug 4;126(30):9152-3
pubmed: 15281783
J Nucl Med. 2012 Aug;53(8):1207-15
pubmed: 22782315
Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2225-2227
pubmed: 31392370
J Nucl Med. 2017 Sep;58(Suppl 2):61S-66S
pubmed: 28864614

Auteurs

Louis Allott (L)

Comprehensive Cancer Imaging Centre, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.

Suraiya Dubash (S)

Comprehensive Cancer Imaging Centre, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.

Eric O Aboagye (EO)

Comprehensive Cancer Imaging Centre, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.

Classifications MeSH